CLINICAL TRIALS PROFILE FOR ELIXOPHYLLIN SR
✉ Email this page to a colleague
All Clinical Trials for ELIXOPHYLLIN SR
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT04551170 ↗ | Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old | Recruiting | Vanderbilt University Medical Center | Phase 2 | 2020-07-13 | Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized by early-onset obesity, short stature and resistance to multiple hormones. This phase 2 clinical trial and open-label extension study will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. We hypothesize that theophylline will cause weight loss, slow the rate of growth plate closure and decrease hormone resistance in children. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ELIXOPHYLLIN SR
Condition Name
Clinical Trial Locations for ELIXOPHYLLIN SR
Trials by Country
Clinical Trial Progress for ELIXOPHYLLIN SR
Clinical Trial Phase
Clinical Trial Sponsors for ELIXOPHYLLIN SR
Sponsor Name